Mesoblast (MESO) Total Non-Current Liabilities (2015 - 2026)
Mesoblast (MESO) posted Total Non-Current Liabilities of $79.6 million for Q4 2025, down 5.98% sequentially from $84.6 million in Q2 2025, and down 33.32% YoY from $119.3 million in Q4 2024.
Analysis
Mesoblast (MESO) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Mesoblast has reported Total Non-Current Liabilities for 11 years, with the latest figure at $79.6 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 33.32% year-over-year to $79.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $79.6 million (down 33.32% YoY) and the FY2025 annual result came in at $84.6 million, down 26.78% from the prior year.
- Total Non-Current Liabilities slipped to $79.6 million in Q4 2025 per MESO's latest filing, from $84.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $130.2 million in Q4 2023 and troughed at $66.6 million in Q1 2021.
- A 5-year average of $102.5 million and a median of $112.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities sank 34.2% in 2021, then jumped 68.61% in 2022.
- Over 5 years, Total Non-Current Liabilities stood at $111.0 million in 2021, then grew by 2.26% to $113.5 million in 2022, then gained by 14.72% to $130.2 million in 2023, then declined by 8.36% to $119.3 million in 2024, then slumped by 33.32% to $79.6 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $79.6 million, $84.6 million, and $119.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 123.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 123.56 Mn |
| Dec 31, 2025 | 79.55 Mn |
| Jun 30, 2025 | 84.62 Mn |
| Dec 31, 2024 | 10.58 Mn |
| Jun 30, 2024 | 115.56 Mn |
| Dec 31, 2023 | 17.07 Mn |
| Jun 30, 2023 | 16.61 Mn |
| Mar 31, 2023 | 8.17 Mn |
| Dec 31, 2022 | 9.00 Mn |
| Sep 30, 2022 | 9.85 Mn |
| Jun 30, 2022 | 12.52 Mn |
| Mar 31, 2022 | 13.18 Mn |
| Dec 31, 2021 | 110.98 Mn |
| Sep 30, 2021 | 69.17 Mn |
| Jun 30, 2021 | 17.02 Mn |
| Mar 31, 2021 | 17.82 Mn |
| Dec 31, 2020 | 19.44 Mn |
| Sep 30, 2020 | 20.72 Mn |
| Jun 30, 2020 | 27.56 Mn |
| Mar 31, 2020 | 28.11 Mn |